For instance, it was recently reported that patients with EBV-positive NHL responded to pembrolizumab more efficiently than those with EBV-negative NHL, presumably due to high PD-L1 expression in EBV-positive NHL [112]. The gene discussed is CD274; the disease is non-Hodgkin lymphoma.